2024-03-27 09:00 | UU:SRNE | | News Release200 | Scilex Holding Company Announces that the U.S. Bankruptcy Court has Extended the Lockup Period on Shares of Scilex Stock Previously Distributed by Sorrento to its Stockholders as a Dividend |
2024-03-02 15:25 | UU:SRNE | | News Release200 | Scilex Holding Company Announces that the Official Committee of Unsecured Creditors of Sorrento Therapeutics, Inc., has Filed a Motion with the U.S. Bankruptcy Court to Extend the Lockup Period on Shares of Scilex Stock Previously Distributed by Sorrento |
2023-10-07 19:28 | UU:SRNE | | News Release200 | Scilex Holding Company Retains Warshaw Burstein, LLP and Christian Attar Law to Investigate Potential Naked Short Selling, Short Positions, Stock Lending Program Activities and Market Manipulation of Its Stock Price |
2023-10-04 13:00 | UU:SRNE | | News Release200 | Scilex Holding Company Provides Notice to All Lenders of Short Positions in the Restricted Dividend Shares of Scilex Holding Company |
2023-10-03 09:00 | UU:SRNE | | News Release200 | Scilex Holding Company Provides Notice to All Record Holders and Beneficial Owners of Restricted Shares of Scilex Holding Company |
2023-09-22 11:38 | UU:SRNE | | News Release200 | Sorrento Therapeutics, Inc. Announces the Consummation of the Previously Announced Sale of Substantially All of the Common Shares, Preferred Shares and Warrants that Sorrento Held in Scilex Holding Company |
2023-09-21 16:05 | UU:SRNE | | News Release200 | Scilex Holding Company Announces the Consummation of the Previously Announced Purchase of all of the Scilex Common Shares, Preferred Shares and Warrants Owned by Sorrento Therapeutics, Inc. |
2023-09-14 09:00 | UU:SRNE | | News Release200 | Scilex Holding Company Announces the Completion of its SP-103 (lidocaine topical system) 5.4%, Triple Strength Formulation of ZTlido ‚ ®, Phase 2 trial which achieved its objectives to Evaluate the Safety and Efficacy of SP-103 in Subjects with Moderate t |
2023-09-13 09:00 | UU:SRNE | | News Release200 | Scilex Holding Company Enters into Non-Binding Term Sheets for the Purchase of all of the Scilex Common Shares, Preferred Shares, and Warrants Currently Owned by Sorrento Therapeutics, Inc. and is Declared the New Successful Bidder |
2023-09-12 09:00 | UU:SRNE | | News Release200 | Sorrento Announces Phase 3 Trial Met Primary Endpoint and Key Secondary Endpoint in Mild or Moderate COVID-19 Adult Patients Treated with Ovydso (Olgotrelvir), an Oral Mpro Inhibitor as a Standalone Treatment for COVID-19 |
2023-09-12 09:00 | UU:SRNE | | News Release200 | Scilex Holding Company Presented Oral and Poster Presentations on ZTlido (lidocaine topical system) at the 2023 Annual PAINWeek Conference Held in Las Vegas, NV |
2023-09-11 09:00 | UU:SRNE | | News Release200 | Scilex Holding Company Generates Record Monthly Revenue In August 2023 And Provides Certain Preliminary Unaudited Financial Results For Gross And Net Sales For The One Month Ended August 2023, And Year-To-Date As Of August 31 2023, Based On Currently Avai |
2023-09-07 09:00 | UU:SRNE | | News Release200 | Sorrento Therapeutics Announces Positive Phase 2a Clinical Trial Results for Resiniferatoxin (RTX) for the Treatment of Knee Pain in Moderate to Severe Osteoarthritis of the Knee (OAK) Patients |
2023-08-08 09:50 | UU:SRNE | | News Release200 | Sorrento Therapeutics, Inc. Announces Auction for Sale of Scilex Securities and Bankruptcy Court Approval of Stalking Horse Bid |
2023-07-27 09:00 | UU:SRNE | | News Release200 | Sorrento Issues a ¢ € œFAQ ¢ € in Response to Large Number Of Urgent Requests from Scilex Dividend Short Holders and/or Record Holders |
2023-07-21 17:53 | UU:SRNE | | News Release200 | /C O R R E C T I O N -- Sorrento Therapeutics, Inc./ |
2023-07-21 09:00 | UU:SRNE | | News Release200 | Sorrento Announces Launch of Voluntary Offering to Dividend Short Holders with Deadline to Participate by July 27, 2023 |
2023-07-20 09:00 | UU:SRNE | | News Release200 | Sorrento Therapeutics, Inc.'s Bankruptcy Court Approves Elective Offering of Restricted Common Stock of Scilex Holding Company for Dividend Short Holders |
2023-07-05 09:00 | UU:SRNE | | News Release200 | Sorrento Announces Positive Phase IIa Study Results of Abivertinib for the Treatment of Relapsed/Refractory Marginal Zone Lymphoma (R/R MZL) and Its Plan for a Pivotal Phase III Study |
2023-06-26 09:00 | UU:SRNE | | News Release200 | Sorrento Announces the Full Enrollment of the Pivotal Phase 3 Trial with Olgotrelvir (OVYDSOTM) (STI-1558), a Second Generation Oral Mpro Inhibitor, as a Standalone Treatment for COVID-19 |
2023-06-16 09:00 | UU:SRNE | | News Release200 | Scilex Holding Company to Present Data on ELYXYB ¢ „ ¢ (celecoxib oral solution) at the 65th Annual Scientific Meeting of the American Headache Society, in Austin, TX. |
2023-06-15 09:03 | UU:SRNE | | News Release200 | Scilex Holding Company Announces that Sorrento Therapeutics, Inc. ¢ € ™s Bankruptcy Court Issues Temporary Restraining Order Against Brokerage Firms and Suspends Short-Sales of Dividended Scilex Stock |
2023-06-15 09:00 | UU:SRNE | | News Release200 | Sorrento Therapeutics, Inc.'s Bankruptcy Court Issues Temporary Restraining Order Against Brokerage Firms and Suspends Short-Sales of Dividended Scilex Stock |
2023-06-13 09:00 | UU:SRNE | | News Release200 | Sorrento Therapeutics, Inc. announces a $4.6 Million U.S. Government contract from the NIAID for a Sensitive, Reusable, and Rapid Diagnostic Platform for Pandemic Preparedness |
2023-06-05 09:00 | UU:SRNE | | News Release200 | Shanghai Escugen Biotechnology Co., Ltd., a partner of Levena Biopharma, a Sorrento Company, releases positive results from a first-in-human study of ESG401, a TROP2 Antibody Drug Conjugate in patients with locally advanced/metastatic solid tumors at the |
2023-06-01 12:29 | UU:SRNE | | News Release200 | Scilex Holding Company provides certain preliminary unaudited financial results for gross and net Sales for the one month ended May 2023, and year-to-date May 2023, based on currently available information |
2023-05-31 15:16 | UU:SRNE | | News Release200 | Scilex Holding Company Enters Master Distributor Agreement Among CH Trading Group LLC ( ¢ € œCHT ¢ € or ¢ € œTerritories Distributor ¢ € ) and Farouk, Maamoun Tamer & Co. ( ¢ € œMaster Distributor ¢ € ) For the Distribution of ZTlido ‚ ® in the Kingd |
2023-05-22 09:00 | UU:SRNE | | News Release200 | Scilex Holding Company Added to the Preliminary List of the Russell 3000 ‚ ® Index and the Small-Cap Russell 2000 ‚ ® Index as part of the 2023 Russell Indexes Annual Reconstitution in June 2023 |
2023-05-14 15:00 | UU:SRNE | | News Release200 | Sorrento Therapeutics, Inc.'s Bankruptcy Court Orders Brokerage Firms to Credit Dividended Scilex Stock to Customers' Accounts and Sorrento Advises Holders of Dividended Scilex Stock to Contact Brokerage Firms to Deliver the Stock to Individual Accounts |